Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313

• Date : 14/09/2022
• 21    
  1

Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD

• Date : 14/09/2022
• 16    
  0

Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study

• Date : 14/09/2022
• 15    
  0

Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study

• Date : 14/09/2022
• 9    
  0

Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801

• Date : 14/09/2022
• 8    
  0

Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study

• Date : 14/09/2022
• 8    
  0

Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study

• Date : 14/09/2022
• 6    
  0

ESMO Gynaecological Cancers Congress 2024

• Date : 20/06/2024
• 10774    
  0

SIFEM 2024

• Date : 13/06/2024
• 2080    
  0

Annual Meeting on Women's Cancer SGO 2024

• Date : 16/03/2024
• 1899    
  0

43ème Réunion interdisciplinaire de chimiothérapie anti-infectieuse

• Date : 18/12/2023
• 10245    
  0

13e Congrès National des réseaux en Cancérologie - CNRC 2023

• Date : 09/11/2023
• 7341    
  0